Enbrel
NDC Package 58406-446-04

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Enbrel is a medication used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Marketed by Immunex Corporation, this product is identified by NDC 58406-446 and is authorized under FDA application BLA103795.

Identification & Billing

NDC Package Code
58406-446-04
Package Description
4 SYRINGE in 1 CARTON / 1 mL in 1 SYRINGE (58406-446-01)
Product Code
58406-446
11-Digit Billing Format
58406044604

Clinical Specifications

Proprietary Name
Enbrel
Dosage Form
-
Usage Information
This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

Regulatory & Marketing

Labeler Name
Immunex Corporation
FDA Application #
BLA103795
Marketing Category
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date
10-20-2017
End Marketing Date
08-02-2024
Listing Expiration
08-02-2024
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 58406-446-04 identifies a specific commercial package of 4 syringe in 1 carton / 1 ml in 1 syringe (58406-446-01) of Enbrel, labeled by Immunex Corporation. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Immunex Corporation on October 20, 2017. The current certification is valid through August 02, 2024.

What are the primary indications for this medication?

This medication is used alone or in combination with an immunosuppressant (such as methotrexate) to treat certain types of arthritis (such as rheumatoid, psoriatic, juvenile idiopathic, and ankylosing spondylitis). Some brands of this medication are also used to treat a skin condition called psoriasis. These conditions are caused by an overactive immune system (autoimmune disease). The immune system attacks the body's own healthy cells, causing inflammation in the joints and skin. Etanercept controls your body's defensive response by blocking the action of a certain natural substance (TNF) that is used by the immune system. Treatment decreases redness, itching and scaly patches in psoriasis as well as the pain, swelling and stiffness of joints in arthritis. This medication can stop the progression of disease and joint damage, resulting in improved daily functioning and quality of life. This medication treats but does not cure autoimmune diseases. Symptoms usually return within 1 month of stopping the medication.

How is this Immunex Corporation product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 58406044604. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
58406-446-04
11-Digit CMS (5-4-2)
58406-0446-04

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.